Delaware Health News Online
SEE OTHER BRANDS

The latest health and wellness news from Delaware

Delaware Health News Online: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Delaware Health News Online.

Press releases published on August 5, 2025

LifeMD Reports Second Quarter 2025 Results

LifeMD Reports Second Quarter 2025 Results

Total revenue increased 23% year-over-year to $62.2 million; adjusted EBITDA rose 223% to $7.1 million Telehealth revenue increased 30% to $48.6 million; telehealth adjusted EBITDA rose 560% to $3.4 million Generated more than $8 million of operating cash …

OraSure Announces Second Quarter 2025 Financial Results

OraSure Announces Second Quarter 2025 Financial Results

BETHLEHEM, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended June 30, 2025 …

Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results

Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results

SEATTLE, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products …

OrthoPediatrics Corp. Reports Second Quarter 2025 Financial Results and Increases Full Year 2025 Revenue Guidance

OrthoPediatrics Corp. Reports Second Quarter 2025 Financial Results and Increases Full Year 2025 Revenue Guidance

WARSAW, Ind., Aug. 05, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the second …

Clover Health Reports Second Quarter 2025 Results; Delivering Strong Sustainable Growth

Clover Health Reports Second Quarter 2025 Results; Delivering Strong Sustainable Growth

Second quarter 2025 Medicare Advantage membership of 106,323, up 32% year-over-year Second quarter 2025 Total revenues of $478 million, up 34% year-over-year Second quarter 2025 profitability metrics with GAAP Net loss of $11 million, Adjusted EBITDA of $ …

Fractyl Health Reports Potent and Durable Two-Year Real-World Outcomes with Revita® Showing Sustained Weight Loss and Improved Glucose Control After a Single Procedure

Fractyl Health Reports Potent and Durable Two-Year Real-World Outcomes with Revita® Showing Sustained Weight Loss and Improved Glucose Control After a Single Procedure

Two-year follow-up in Germany Real-World Registry study showed median 9.6% weight loss and 1.6% HbA1c reduction after a single Revita procedure in participants with type 2 diabetes, with no device- or procedure-related serious adverse events to date New …

Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025

Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025

SCOTTSDALE, Ariz., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug …

Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne

Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne

Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne Year-over-year Q2 revenues increased by 20% to $26.6 million Adjusted EBITDA …

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to …

BridgeBio Reports Second Quarter 2025 Financial Results and Business Updates

BridgeBio Reports Second Quarter 2025 Financial Results and Business Updates

- As of August 1, 2025, 3,751 unique patient prescriptions have been written by 1,074 unique prescribers, representing an accelerating launch driven by strong month over month growth in the crucial treatment naïve patient segment - $110.6 million in total …

SIGA Reports Financial Results for Three and Six Months Ended June 30, 2025

SIGA Reports Financial Results for Three and Six Months Ended June 30, 2025

NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Generated Product Revenues of $79 million for the Three Months Ended June 30 Awarded Additional Development Funding of $27 million under the BARDA 19C Contract during the Three Months Ended June 30 Corporate …

OrthoPediatrics Corp. Announces Continued Expansion of Specialty Bracing Division Into New Territories with Multiple Clinics

OrthoPediatrics Corp. Announces Continued Expansion of Specialty Bracing Division Into New Territories with Multiple Clinics

WARSAW, Ind., Aug. 05, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the expansion of its OrthoPediatrics …

Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update

Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update

Second quarter total revenue of $166 million, Crysvita® revenue of $120 million and Dojolvi® revenue of $23 million Reaffirm 2025 Revenue Guidance: Total revenue between $640 million to $670 million, Crysvita revenue of $460 million to $480 million, and …

Jushi Holdings Inc. Reports Second Quarter 2025 Financial Results

Jushi Holdings Inc. Reports Second Quarter 2025 Financial Results

Revenue of $65.0 million, Reflecting Year-over-Year and Sequential Growth Net Loss of $12.3 million, Compared to $17.0 million in the First Quarter of 2025 Adjusted EBITDA Increased 39.6% Quarter-over-Quarter to $13.7 million, Up From $9.8 million in Q1 …

Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025

Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025

NEWTON, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the …

Day One Reports Second Quarter 2025 Financial Results and Corporate Progress

Day One Reports Second Quarter 2025 Financial Results and Corporate Progress

OJEMDA™ (tovorafenib) net product revenue of $33.6 million in Q2 2025, a 10% quarter-over-quarter increase OJEMDA full-year 2025 net product revenue expected to be $140 to $150 million Ended the second quarter with $453.1 million in cash, cash equivalents …

Pacira BioSciences Reports Second Quarter 2025 Financial Results

Pacira BioSciences Reports Second Quarter 2025 Financial Results

-- Solid execution across corporate, clinical and commercial initiatives -- -- Several key milestones advance 5x30 path to growth -- -- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. ( …

IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call

IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call

Investors are reminded that Shareholders of record as of August 7, 2025, will receive a 15% stock dividend payment LAWRENCEVILLE, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its …

Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology

Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology

Tevogen.AI to explore external market opportunities as a potential revenue source. Beta version to incorporate oncology targets, enhancing the accuracy and diversity of the PredicTcell model and potentially accelerating cancer immunotherapy development. …

PBGH Announces Aurora Chen as Vice President of Advisory Services

PBGH Announces Aurora Chen as Vice President of Advisory Services

Oakland, California, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Purchaser Business Group on Health (PBGH), a nonprofit coalition representing 40 private employers and public entities across the U.S., announces strategic human capital leader, health advisor and …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions